Which has preferable earnings and valuation, ANVS or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is ANVS or ALXO more profitable?

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% ALX Oncology N/A -124.06% -85.57%

Does the media refer more to ANVS or ALXO?

In the previous week, ALX Oncology had 3 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 1.77 beat Annovis Bio's score of 1.34 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate SIGA or ANVS?

Annovis Bio has a consensus price target of $11.67, suggesting a potential upside of 564.77%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Does the media prefer SIGA or ANVS?

In the previous week, Siga Technologies had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Siga Technologies and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Siga Technologies' score of 0.38 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TARA or ANVS?

Protara Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is TARA or ANVS more profitable?

Protara Therapeutics' return on equity of -38.70% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Annovis Bio N/A -318.08% -215.47%

Which has better earnings & valuation, ANVS or CGEN?

Compugen has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Compugen $72.76M 3.05 $35.34M $0.37 6.35

Does the media refer more to ANVS or CGEN?

In the previous week, Compugen had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Compugen and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Compugen's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANVS or RNAC?

In the previous week, Cartesian Therapeutics had 5 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Cartesian Therapeutics and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Cartesian Therapeutics' score of 0.95 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annovis Bio (ANVS) Competitors

$1.76 -0.02 (-0.85%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$1.74 -0.01 (-0.80%)

As of 07/31/2026 07:55 PM Eastern

Compare

ANVS vs. ALXO, SIGA, TARA, CGEN, and RNAC

Should you buy Annovis Bio stock or one of its competitors? MarketBeat compares Annovis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annovis Bio include ALX Oncology (ALXO), Siga Technologies (SIGA), Protara Therapeutics (TARA), Compugen (CGEN), and Cartesian Therapeutics (RNAC).

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, ALX Oncology had 3 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 1.77 beat Annovis Bio's score of 1.34 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
ALX Oncology	N/A	-124.06%	-85.57%

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Annovis Bio currently has a consensus price target of $11.67, suggesting a potential upside of 564.77%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 137.11%. Given Annovis Bio's higher possible upside, equities analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Annovis Bio has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

ALX Oncology beats Annovis Bio on 9 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Siga Technologies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Siga Technologies had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Siga Technologies and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Siga Technologies' score of 0.38 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a consensus price target of $11.67, suggesting a potential upside of 564.77%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Siga Technologies has a net margin of 21.58% compared to Annovis Bio's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Annovis Bio	N/A	-318.08%	-215.47%

Siga Technologies has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.48	$23.28M	$0.27	12.11
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Summary

Siga Technologies beats Annovis Bio on 9 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Annovis Bio had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for Protara Therapeutics. Annovis Bio's average media sentiment score of 1.34 beat Protara Therapeutics' score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Annovis Bio	Positive

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 569.64%. Annovis Bio has a consensus target price of $11.67, suggesting a potential upside of 564.77%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Protara Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Protara Therapeutics' return on equity of -38.70% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Annovis Bio	N/A	-318.08%	-215.47%

Protara Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Protara Therapeutics beats Annovis Bio on 8 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Compugen?

Annovis Bio (NYSE:ANVS) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Compugen had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Compugen and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Compugen's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio presently has a consensus target price of $11.67, suggesting a potential upside of 564.77%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 112.77%. Given Annovis Bio's higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Annovis Bio has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Compugen has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Compugen has a net margin of 47.97% compared to Annovis Bio's net margin of 0.00%. Compugen's return on equity of 47.72% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Compugen	47.97%	47.72%	27.51%

Compugen has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Compugen	$72.76M	3.05	$35.34M	$0.37	6.35

Summary

Compugen beats Annovis Bio on 11 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Cartesian Therapeutics?

Annovis Bio (NYSE:ANVS) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Annovis Bio has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Annovis Bio has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Cartesian Therapeutics	$2.80M	81.84	-$130.30M	-$5.90	N/A

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cartesian Therapeutics had 5 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Cartesian Therapeutics and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Cartesian Therapeutics' score of 0.95 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Annovis Bio presently has a consensus price target of $11.67, indicating a potential upside of 564.77%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 317.95%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Annovis Bio beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$60.63M	$3.55B	$7.16B	$23.68B
Dividend Yield	N/A	3.78%	2.59%	4.22%
P/E Ratio	-1.03	7.38	282.25	31.00
Price / Sales	N/A	1,254.29	583.24	19.07
Price / Cash	N/A	98.58	71.23	31.30
Price / Book	2.74	16.80	11.09	4.62
Net Income	-$28.85M	-$12.46M	$3.50B	$1.07B
7 Day Performance	6.04%	-1.47%	-0.24%	0.35%
1 Month Performance	-9.30%	-8.45%	-3.70%	-0.55%
1 Year Performance	-30.08%	48.32%	61.98%	19.21%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	3.4603 of 5 stars	$1.76 -0.8%	$11.67 +564.8%	-30.1%	$60.63M	N/A	N/A	3	News Coverage Positive News Gap Up
ALXO ALX Oncology	2.5051 of 5 stars	$1.95 -3.4%	$4.60 +135.8%	+274.4%	$263.07M	N/A	N/A	40	News Coverage Positive News
SIGA Siga Technologies	0.6436 of 5 stars	$3.03 -2.4%	N/A	-49.4%	$219.12M	$93.78M	11.31	40	News Coverage Positive News Upcoming Earnings
TARA Protara Therapeutics	1.8262 of 5 stars	$3.86 -4.4%	$26.25 +579.7%	+28.1%	$218.63M	N/A	N/A	30
CGEN Compugen	2.5068 of 5 stars	$2.32 -2.7%	$5.00 +116.0%	+58.8%	$218.51M	$72.66M	6.25	70	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SIGA, TARA, CGEN, and RNAC

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Siga Technologies?

Summary

How does Annovis Bio compare to Protara Therapeutics?

Summary

How does Annovis Bio compare to Compugen?

Summary

How does Annovis Bio compare to Cartesian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SIGA, TARA, CGEN, and RNAC

How does Annovis Bio compare to ALX Oncology?

Does the media refer more to ANVS or ALXO?

Is ANVS or ALXO more profitable?

Which has preferable earnings and valuation, ANVS or ALXO?

Do analysts prefer ANVS or ALXO?

Do insiders & institutionals hold more shares of ANVS or ALXO?

Which has more risk and volatility, ANVS or ALXO?

Summary

How does Annovis Bio compare to Siga Technologies?

Which has more volatility & risk, SIGA or ANVS?

Do institutionals & insiders hold more shares of SIGA or ANVS?

Does the media prefer SIGA or ANVS?

Do analysts rate SIGA or ANVS?

Is SIGA or ANVS more profitable?

Which has better earnings & valuation, SIGA or ANVS?

Summary

How does Annovis Bio compare to Protara Therapeutics?

Does the media prefer TARA or ANVS?

Do insiders & institutionals have more ownership in TARA or ANVS?

Do analysts prefer TARA or ANVS?

Which has preferable valuation & earnings, TARA or ANVS?

Is TARA or ANVS more profitable?

Which has more volatility and risk, TARA or ANVS?

Summary

How does Annovis Bio compare to Compugen?

Does the media refer more to ANVS or CGEN?

Do analysts prefer ANVS or CGEN?

Which has more risk & volatility, ANVS or CGEN?

Do institutionals and insiders have more ownership in ANVS or CGEN?

Is ANVS or CGEN more profitable?

Which has better earnings & valuation, ANVS or CGEN?

Summary

How does Annovis Bio compare to Cartesian Therapeutics?

Which has more risk and volatility, ANVS or RNAC?

Which has stronger valuation & earnings, ANVS or RNAC?

Do insiders and institutionals have more ownership in ANVS or RNAC?

Does the media refer more to ANVS or RNAC?

Is ANVS or RNAC more profitable?

Do analysts recommend ANVS or RNAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools